Applications Software Technology Acquires Symatrix to Accelerate Global Expansion in Oracle Cloud Services
20.5.2024 15:00:00 EEST | Business Wire | Press release
Applications Software Technology (AST), a leading digital transformation solutions provider, today announced the signing of a definitive agreement for the acquisition of IT and Oracle services provider Symatrix. The acquisition of Symatrix, a leading IT and Oracle services provider in the UK, is a meaningful step in AST’s global expansion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240520063933/en/
“The capabilities of Symatrix complement and broaden AST’s core services and allow us to reach new global markets,” said AST CEO Justin Winter. “Working together we will be able to offer enhanced services to our combined customer base. We’ll continue to deliver high-value solutions that provide measurable value and outcomes for our customers at a global scale.”
Symatrix brings an established UK customer base that strengthens AST’s vertical expertise across numerous industries and provides a platform to further expand in emerging sectors. The deep consulting capabilities of Symatrix will also expand AST’s capabilities across Oracle Cloud Applications, including Supply Chain and Human Capital Management.
“AST is a best-in-class enterprise solutions provider that has developed into a premier consultancy for complex Cloud needs across public and commercial industries,” said Chris Brooks, Symatrix CEO. “Joining forces with AST is a natural progression for Symatrix and allows us to service our customers with even greater resources and technical services.”
“AST and Symatrix represent a powerful combination in Oracle Cloud services,” added Charles Phillips -- Managing Partner for Recognize, Chairman of the Board for AST and former President of Oracle. “The complementary end market exposure helps solidify the businesses’ leadership positions across two continents.”
Following the transition, Chris and the leadership team will remain in their roles with a renewed focus on expanding the UK customer base with a new suite of offerings and delivery geographies from AST.
“At AST, we foster a culture of inclusivity and innovation at every level of our organization,” said Winter. “The Symatrix family embodies these values, and our partnership opens a world of exciting possibilities for our customers and employees.”
About Applications Software Technology (AST) LLC
AST is an award-winning, full-service enterprise solution provider, guiding digital transformation for clients in the Government and Commercial Sectors for more than two decades. Clients look to AST for leadership and assistance in transforming their organizations via software solutions, process engineering, and change management. From cloud technology to legacy on-premises applications, AST’s services encompass all aspects of SaaS, PaaS, and IaaS. AST also offers flexible Managed Services, supporting the needs of over 200 customers around the globe. To learn more, visit www.astcorporation.com.
About Symatrix
Symatrix is a United Kingdom based Oracle HCM, ERP and SCM Cloud Consulting, Application Management and Outsourced Payroll provider. Symatrix works with Public Sector and Commercial clients to innovatively help unlock the endless and exciting possibilities of Oracle Cloud.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240520063933/en/
Contact information
Melissa Sider
Phone: (888) AST-0002
Email: msider@astcorporation.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom